enVVeno Medical Corp (NVNO) - Total Liabilities
Based on the latest financial reports, enVVeno Medical Corp (NVNO) has total liabilities worth $2.90 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NVNO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
enVVeno Medical Corp - Total Liabilities Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NVNO total asset value.
enVVeno Medical Corp Competitors by Total Liabilities
The table below lists competitors of enVVeno Medical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IMPRENDIROMA S.P.A.
F:Y37
|
Germany | €31.20 Million |
|
Worksport Ltd
NASDAQ:WKSP
|
USA | $7.90 Million |
|
hGears AG
XETRA:HGEA
|
Germany | €49.78 Million |
|
Rathdowney Resources Ltd
V:RTH
|
Canada | CA$17.57 Million |
|
GD Culture Group Limited
NASDAQ:GDC
|
USA | $1.93 Million |
|
Horisont Energi AS
OL:HRGI
|
Norway | Nkr7.09 Million |
|
Compodium International AB
ST:COMPDM
|
Sweden | Skr26.39 Million |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
Turkey | TL5.13 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down enVVeno Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NVNO equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how enVVeno Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for enVVeno Medical Corp (2014–2024)
The table below shows the annual total liabilities of enVVeno Medical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.79 Million | +14.78% |
| 2023-12-31 | $2.44 Million | -16.95% |
| 2022-12-31 | $2.93 Million | -11.01% |
| 2021-12-31 | $3.29 Million | -4.22% |
| 2020-12-31 | $3.44 Million | +40.74% |
| 2019-12-31 | $2.44 Million | +60.49% |
| 2018-12-31 | $1.52 Million | -81.37% |
| 2017-12-31 | $8.17 Million | +295.56% |
| 2016-12-31 | $2.07 Million | -55.61% |
| 2015-12-31 | $4.66 Million | +28.99% |
| 2014-12-31 | $3.61 Million | -- |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more